Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 1/2012

01-03-2012 | Review

A review on various targeted anticancer therapies

Authors: Junjie Li, Feng Chen, Marlein Miranda Cona, Yuanbo Feng, Uwe Himmelreich, Raymond Oyen, Alfons Verbruggen, Yicheng Ni

Published in: Targeted Oncology | Issue 1/2012

Login to get access

Abstract

Translational oncology aims to translate laboratory research into new anticancer therapies. Contrary to conventional surgery, chemotherapy, and radiotherapy, targeted anticancer therapy (TAT) refers to systemic administration of drugs with particular mechanisms that specifically act on well-defined targets or biologic pathways that, when activated or inactivated, may cause regression or destruction of the malignant process, meanwhile with minimized adverse effects on healthy tissues. In this article, we intend to first give a brief review on various known TAT approaches that are deemed promising for clinical applications in the current trend of personalized medicine, and then we will introduce our newly developed approach namely small molecular sequential dual targeting theragnostic strategy as a generalized class of TAT for the management of most solid malignancies, which, after optimization, is expected to help improve overall cancer treatability and curability.
Literature
1.
Levin PBAB (2008) World Cancer Report 2008; Report No.9789283204237
2.
3.
Meeran SM, Katiyar SK (2008) Cell cycle control as a basis for cancer chemoprevention through dietary agents. Front Biosci 13:2191–2202PubMedCrossRef
4.
Aggarwal BB, Danda D, Gupta S, Gehlot P (2009) Models for prevention and treatment of cancer: problems vs promise. Biochem Pharmacol 78(9):1083–1094PubMedCrossRef
5.
Hamilton A, Gallipoli P, Nicholson E, Holyoake TL (2010) Targeted therapy in haematological malignancies. J Pathol 220(4):404–418PubMed
6.
Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J et al (2004) Targeted therapies for cancer. Am J Clin Pathol 122(4):598–609PubMedCrossRef
7.
Piccaluga PP, Martinelli G, Baccarani M (2006) Advances in the treatment for haematological malignancies. Expert Opin Pharmacother 7(6):721–732PubMedCrossRef
8.
9.
Wachsberger P, Burd R, Dicker AP (2003) Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 9:1957–1971PubMed
10.
Li J, Sun Z, Zhang J, Shao H, Miranda Cona M, Wang H et al (2011) A dual-targeting anticancer approach: soil and seed principle. Radiology 260(3):799–807PubMedCrossRef
11.
Cherry M, Williams DH (2004) Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights. Curr Med Chem 11(6):663–673PubMedCrossRef
12.
McGregor MJ (2007) A pharmacophore map of small molecule protein kinase inhibitors. J Chem Inf Model 47(6):2374–2382PubMedCrossRef
13.
Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353(2):172–187PubMedCrossRef
14.
Pearson MA, Fabbro D (2004) Targeting protein kinases in cancer therapy: a success? Expert Rev Anticancer Ther 4(6):1113–1124PubMedCrossRef
15.
Furge KA, MacKeigan JP, Teh BT (2010) Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. Lancet Oncol 11(6):571–578PubMedCrossRef
16.
Fasolo A, Sessa C (2011) Current and future directions in mammalian target of rapamycin inhibitors development. Expert Opin Investig Drugs 20(3):381–394PubMedCrossRef
17.
Gambacorti-Passerini C (2008) Part I: Milestones in personalised medicine—imatinib. Lancet Oncol 9(6):600PubMedCrossRef
18.
DeAngelo DJ, Ritz J (2004) Imatinib therapy for patients with chronic myelogenous leukemia: are patients living longer? Clin Cancer Res 10(1 Pt 1):1–3PubMedCrossRef
19.
20.
le Coutre P, Kreuzer KA, Pursche S, Bonin M, Leopold T, Baskaynak G et al (2004) Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 53(4):313–323PubMedCrossRef
21.
Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346(9):645–652PubMedCrossRef
22.
Baselga J (2002) Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7(Suppl 4):2–8PubMedCrossRef
23.
Reis-Filho JS, Milanezi F, Carvalho S, Simpson PT, Steele D, Savage K et al (2005) Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 7(6):R1028–R1035PubMedCrossRef
24.
Patra CR, Bhattacharya R, Mukhopadhyay D, Mukherjee P (2010) Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev 62(3):346–361PubMedCrossRef
25.
Mantha AJ, Hanson JE, Goss G, Lagarde AE, Lorimer IA, Dimitroulakos J (2005) Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin Cancer Res 11(6):2398–2407PubMedCrossRef
26.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139PubMedCrossRef
27.
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–1500PubMedCrossRef
28.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388PubMedCrossRef
29.
30.
31.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516PubMedCrossRef
32.
33.
Von Mehren M, Adams GP, Weiner LM (2003) Monoclonal antibody therapy for cancer. Annu Rev Med 54:343–369CrossRef
34.
35.
Zhang Q, Chen G, Liu X, Qian Q (2007) Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. Cell Res 17(2):89–99PubMedCrossRef
36.
Ross JS, Gray K, Gray GS, Worland PJ, Rolfe M (2003) Anticancer antibodies. Am J Clin Pathol 119(4):472–485PubMedCrossRef
37.
Funaro A, Horenstein AL, Santoro P, Cinti C, Gregorini A, Malavasi F (2000) Monoclonal antibodies and therapy of human cancers. Biotechnol Adv 18(5):385–401PubMedCrossRef
38.
39.
Cheson BD, Leonard JP (2008) Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 359(6):613–626PubMedCrossRef
40.
Plosker GL, Figgitt DP (2003) Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 63(8):803–843PubMedCrossRef
41.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182PubMedCrossRef
42.
Menard S, Pupa SM, Campiglio M, Tagliabue E (2003) Biologic and therapeutic role of HER2 in cancer. Oncogene 22(42):6570–6578PubMedCrossRef
43.
Mandler R, Wu C, Sausville EA, Roettinger AJ, Newman DJ, Ho DK et al (2000) Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. J Natl Cancer Inst 92(19):1573–1581PubMedCrossRef
44.
Shukla R, Thomas TP, Peters JL, Desai AM, Kukowska-Latallo J, Patri AK et al (2006) HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem 17(5):1109–1115PubMedCrossRef
45.
Jahanzeb M (2008) Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer 8(4):324–333PubMedCrossRef
46.
Slamon DJL-JB, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792PubMedCrossRef
47.
Tai W, Mahato R, Cheng K (2010) The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 146(3):264–275PubMedCrossRef
48.
Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369(9555):29–36PubMedCrossRef
49.
Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr et al (2007) Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. 2007 ASCO Annual Meeting Proceedings Part I; 25(18S):512
50.
Slamon DJ, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M et al (2006) 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2neu positive early breast cancer patients. Breast Cancer Res Treat 100(suppl 1):LBA 53
51.
Verma S (2008) Trastuzumab in the adjuvant setting: concurrent or sequential? It takes two to tango! Curr Oncol 15(1):66–67PubMedCrossRef
52.
Amoroso A, Hafsi S, Militello L, Russo AE, Soua Z, Mazzarino MC et al (2011) Understanding rituximab function and resistance: implications for tailored therapy. Front Biosci 16:770–782PubMedCrossRef
53.
Hauptrock B, Hess G (2008) Rituximab in the treatment of non-Hodgkin's lymphoma. Biologics 2(4):619–633PubMed
54.
55.
Tortora G, Melisi D, Ciardiello F (2004) Angiogenesis: a target for cancer therapy. Curr Pharm Des 10(1):11–26PubMedCrossRef
56.
Siemann DW, Horsman MR (2009) Vascular targeted therapies in oncology. Cell Tissue Res 335(1):241–248PubMedCrossRef
57.
Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR et al (2005) Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11(2 Pt 1):416–420PubMed
58.
Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58(7):1408–1416PubMed
59.
Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58–62PubMedCrossRef
60.
Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011–1027PubMedCrossRef
61.
O'Hanlon LH (2005) Taking down tumors: vascular disrupting agents entering clinical trials. J Natl Cancer Inst 97(17):1244–1245PubMed
62.
Siemann DW (2011) The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev 37(1):63–74, Epub 2010 Jun 8PubMedCrossRef
63.
Griffioen AW, Molema G (2000) Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52(2):237–268PubMed
64.
65.
66.
67.
Eskens FA, Sleijfer S (2008) The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit? Eur J Cancer 44(16):2350–2356PubMedCrossRef
68.
Uronis HE, Hurwitz HI (2007) Is bevacizumab effective and safe in combination with chemotherapy in patients with colorectal cancer? Nat Clin Pract Oncol 4(4):214–215PubMedCrossRef
69.
70.
Gotink KJ, Verheul HM (2010) Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 13(1):1–14PubMedCrossRef
71.
72.
Gridelli C, Rossi A, Maione P, Rossi E, Castaldo V, Sacco PC et al (2009) Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist 14(6):612–620PubMedCrossRef
73.
Zhao L, Ching LM, Kestell P, Kelland LR, Baguley BC (2005) Mechanisms of tumor vascular shutdown induced by 5, 6-dimethylxanthenone-4-acetic acid (DMXAA): increased tumor vascular permeability. Int J Cancer 116(2):322–326PubMedCrossRef
74.
Wang H, Sun X, Chen F, De Keyzer F, Yu J, Landuyt W et al (2009) Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. Investig Radiol 44(1):44–53CrossRef
75.
Miederer M, McDevitt MR, Sgouros G, Kramer K, Cheung NK, Scheinberg DA (2004) Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med 45(1):129–137PubMed
76.
Lewington VJ, Clarke SE, Hoefnagel CA, Behr TM, Brans B, deKlerk J, Vieira MR (2003) 131I mIBG therapy: results of a European Survey. Presented at European Association of Nuclear Medicine Medicine Meeting, August 2003, Amsterdam
77.
78.
79.
Weiner RE, Thakur ML (2005) Radiolabeled peptides in oncology: role in diagnosis and treatment. BioDrugs 19(3):145–163PubMedCrossRef
80.
Oyen WJ, Bodei L, Giammarile F, Maecke HR, Tennvall J, Luster M et al (2007) Targeted therapy in nuclear medicine—current status and future prospects. Ann Oncol 18(11):1782–1792PubMedCrossRef
81.
Okarvi SM (2008) Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer. Cancer Treat Rev 34(1):13–26PubMedCrossRef
82.
Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X et al (2006) Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A 103(44):16436–16441PubMedCrossRef
83.
Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ (2007) Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 46(6):723–734PubMedCrossRef
84.
Mariani G, Erba PA, Signore A (2006) Receptor-mediated tumor targeting with radiolabeled peptides: there is more to it than somatostatin analogs. J Nucl Med 47(12):1904–1907PubMed
85.
Giammarile F, Chiti A, Lassmann M, Brans B, Flux G (2008) EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging 35(5):1039–1047PubMedCrossRef
86.
Shapiro B, Sisson JC, Wieland DM, Mangner TJ, Zempel SM, Mudgett E et al (1991) Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]-metaiodobenzylguanidine: results from ten years of experience. J Nucl Biol Med 35(4):269–276PubMed
87.
DuBois SG, Matthay KK (2008) Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol 35(Suppl 1):S35–S48PubMedCrossRef
88.
Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5(2):147–159PubMedCrossRef
89.
Schaefer NG, Ma J, Huang P, Buchanan J, Wahl RL (2010) Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists. J Nucl Med 51(6):987–994PubMedCrossRef
90.
Jacobs SA (2007) Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects. Biologics 1(3):215–227PubMed
91.
Chen FM, Taylor CR, Epstein AL (1989) Tumor necrosis treatment of ME-180 human cervical carcinoma model with 131I-labeled TNT-1 monoclonal antibody. Cancer Res 49(16):4578–4585
92.
Shapiro WR, Carpenter SP, Roberts K, Shan JS (2006) (131)I-chTNT-1/B mAb: tumour necrosis therapy for malignant astro-cytic glioma. Expert Opin Biol Ther 6(5):539–545PubMedCrossRef
93.
Khawli LA, Mizokami MM, Sharifi J, Hu P, Epstein AL (2002) Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin. Cancer Biother Radiopharm17(4):359–370
94.
Chen S, Yu L, Jiang C, Zhao Y, Sun D, Li S et al (2005) Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol 23(7):1538–1547PubMedCrossRef
95.
Ni Y, Bormans G, Chen F, Verbruggen A, Marchal G (2005) Necrosis avid contrast agents: functional similarity versus structural diversity. Investig Radiol 40(8):526–535CrossRef
96.
Ni Y (2008) Metalloporphyrins and functional analogues as MRI contrast agents. Curr Med Imaging Rev 4:96–112CrossRef
97.
Ni Y, Marchal G, Yu J, Lukito G, Petre C, Wevers M et al (1995) Localization of metalloporphyrin-induced “specific” enhancement in experimental liver tumors: comparison of magnetic resonance imaging, microangiographic, and histologic findings. Acad Radiol 2(8):687–699PubMedCrossRef
98.
Ni Y, Pislaru C, Bosmans H, Pislaru S, Miao Y, Bogaert J et al (2001) Intracoronary delivery of Gd-DTPA and Gadophrin-2 for determination of myocardial viability with MR imaging. Eur Radiol 11(5):876–883PubMedCrossRef
99.
Van de Putte M, Ni Y, De Witte PA (2008) Exploration of the mechanism underlying the tumor necrosis avidity of hypericin. Oncol Rep 19(4):921–926PubMed
100.
Ni Y, Huyghe D, Verbeke K, de Witte PA, Nuyts J, Mortelmans L et al (2006) First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imaging 33(5):595–601PubMedCrossRef
101.
Fonge H, Jin L, Wang H, Ni Y, Bormans G, Verbruggen A (2007) Synthesis and preliminary evaluation of mono-[123I]iodohypericin monocarboxylic acid as a necrosis avid imaging agent. Bioorg Med Chem Lett 17(14):4001–4005PubMedCrossRef
102.
Van de Putte M, Wang H, Chen F, De Witte PA, Ni Y (2008) Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model. Oncol Rep 19(4):927–932PubMed
103.
Van de Putte M, Wang H, Chen F, de Witte PA, Ni Y (2008) Hypericin as a marker for determination of tissue viability after intratumoral ethanol injection in a murine liver tumor model. Acad Radiol 15(1):107–113PubMedCrossRef
104.
Brown JM (2007) Tumor hypoxia in cancer therapy. Methods Enzymol 435:297–321PubMed
105.
106.
Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG et al (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23(3):329–336PubMedCrossRef
107.
Chari RV (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 41(1):98–107PubMedCrossRef
108.
De Bono JS, Tolcher AW, Rowinsky EK (2003) The future of cytotoxic therapy: selective cytotoxicity based on biology is the key. Breast Cancer Res 5(3):154–159PubMedCrossRef
109.
Strome SE, Sausville EA, Mann D (2007) A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 12(9):1084–1095PubMedCrossRef
110.
Linenberger ML, Maloney DG, Bernstein ID (2002) Antibody-directed therapies for hematological malignancies. Trends Mol Med 8(2):69–76PubMedCrossRef
111.
Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M et al (2011) Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 59(4):526–540PubMedCrossRef
112.
Seruga B, Gan HK, Knox JJ (2009) Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer. Curr Oncol 16(Suppl 1):S52–S59PubMed
113.
114.
Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ et al (2005) Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4(1):101–112PubMed
115.
Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912–1934PubMedCrossRef
116.
117.
Costantini DL, Hu M, Reilly RM (2008) Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. Cancer Biother Radiopharm 23(1):3–24PubMedCrossRef
118.
Bidros DS, Liu JK, Vogelbaum MA, Debinski W, Tatter SB (2009) Future of convection-enhanced delivery in the treatment of brain tumors. Future Oncol 6(1):117–125PubMed
119.
O’Donnell RT (2006) Nuclear localizing sequences: an innovative way to improve targeted radiotherapy. J Nucl Med 47(5):738–739PubMed
120.
Metadata
Title
A review on various targeted anticancer therapies
Authors
Junjie Li
Feng Chen
Marlein Miranda Cona
Yuanbo Feng
Uwe Himmelreich
Raymond Oyen
Alfons Verbruggen
Yicheng Ni
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Targeted Oncology / Issue 1/2012
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-012-0212-2

Other articles of this Issue 1/2012

Targeted Oncology 1/2012 Go to the issue

Review

Advancement in the research on vascular endothelial growth inhibitor (VEGI)

Review

Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival

Editorial

Recent successes of cancer immunotherapy: a new dimension in personalized medicine?

Review

Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility?

Review

Targeting pattern recognition receptors in cancer immunotherapy

Review

Targeting regulatory T cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits